Dose adjustment in renal impairment
Dose adjustment may be needed in kidney disease.
Leaflet ABATIXENT 5mg film-coated tablets
Precautions:
Major drug interactions
This medicine may have important interactions with other medicines.
Additional monitoring
This medicine is subject to additional monitoring.
Breastfeeding warning
Use during breastfeeding only on medical advice.
Pregnancy warning
Use during pregnancy only on medical advice.
Bleeding risk
This medicine may increase the risk of bleeding.
Apixaban is an oral anticoagulant from the class of direct factor Xa inhibitors, used for the prevention and treatment of thromboembolic disorders. It is indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Apixaban works by inhibiting factor Xa, an essential enzyme in the coagulation process, thereby reducing the formation of blood clots. Unlike traditional anticoagulants such as warfarin, apixaban does not require regular INR (prothrombin time) monitoring and has fewer drug interactions.
Common side effects include minor bleeding, such as nosebleeds (epistaxis) or bruising. In rare cases, severe bleeding, such as gastrointestinal or intracranial hemorrhage, may occur. Patients should inform their doctor about any signs of unusual bleeding.
Apixaban should be used with caution in patients with severe renal impairment, liver disease, or an increased risk of bleeding. It is contraindicated in patients with active bleeding or those undergoing treatments that significantly increase the risk of hemorrhage.
Apixaban works by inhibiting factor Xa, an essential enzyme in the coagulation process, thereby reducing the formation of blood clots. Unlike traditional anticoagulants such as warfarin, apixaban does not require regular INR (prothrombin time) monitoring and has fewer drug interactions.
Common side effects include minor bleeding, such as nosebleeds (epistaxis) or bruising. In rare cases, severe bleeding, such as gastrointestinal or intracranial hemorrhage, may occur. Patients should inform their doctor about any signs of unusual bleeding.
Apixaban should be used with caution in patients with severe renal impairment, liver disease, or an increased risk of bleeding. It is contraindicated in patients with active bleeding or those undergoing treatments that significantly increase the risk of hemorrhage.
General data about ABATIXENT 5mg
- Substance:
- apixaban
- Date of latest medicines list:
- 01-11-2023
- Product code:
- W69800001
- Concentration:
- 5mg
- Pharmaceutical form:
- film-coated tablets
- Quantity:
- 10
- Product type:
- Generic medicine
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for apixaban
Concentrations available for apixaban
- 1.25mg/ml
- 2.5mg
- 5mg